Diaceutics PLC

("Diaceutics" or the "Company")

Issue of Share Options/PDMR Shareholdings

New York, Belfast and London, 23 July 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the issue of 1,886,357 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

Share Options were granted as follows:

For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.

The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.

The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 6,211,466 representing approximately 7.32% of its current issued share capital of 84,812,636.

Enquiries: 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.